Will the AACR Annual Meeting 2026 (closing April 22) feature a press-released abstract reporting a tumor response rate above 50% for a novel ADC (antibody-drug conjugate) in a breast cancer trial?

AACR publishes a press release between April 20–22, 2026 specifically highlighting an ADC therapy with a tumor response rate exceeding 50% in a breast cancer clinical trial Source: AACR official press releases at aacr.org/meeting/aacr-annual-meeting-2026/press-releases/